Docusign Inc vs Medpace Holdings Inc — how do they compare? Docusign Inc trades at $57.81 (market cap $11.33B), while Medpace Holdings Inc trades at $598.37 (market cap $16.90B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Docusign Inc nearer its low. Which is the better fit depends on your goals.
| DOCU | MEDP | |
|---|---|---|
Market Cap | $11.33B | $16.90B |
Sector | Technology | Technology |
52-Week High | $85.01 | $620.59 |
52-Week Low | $41.75 | $393.42 |
Enterprise Value | $10.70B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $57.89, down 2.93% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.09 exceeding expectations. Revenue growth remains steady, reaching $2.98B in 2025, while profitability improved significantly with a net income margin of 35.87%.
The outlook is mixed with solid fundamentals supporting long-term growth, but valuation multiples appear elevated. Key risks include competitive pressures and market volatility. Analyst consensus is cautious with a $55.40 price target below current levels, suggesting limited near-term upside despite positive operational trends.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Trailing returns across standard periods
Latest headlines on both assets
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →